In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
What are schools doing to help youth mental health?
Are small, family-run businesses dying in Canada?
The dark side of collagen
Ford government targets school lands to build housing
How a former Libyan dictator’s money ended up in Canada
New details emerge about Montreal’s deadliest fire in decades
What happens for Tibet when the Dalai Lama dies
Why storms are more destructive now
An ex-RCMP officer, a real estate tycoon and Operation Fox Hunt
The problem with building more housing
What it’s like to escape from wildfires
Where’s that recession? Why it’s still too early to celebrate
Connie Walker’s latest investigation: Her own family's history
A reality check on the fertility promises of egg-freezing
Dispatch calls reveal chaos of deadly floods in Nova Scotia
The unknown health impacts of cannabis smoke
Ford accused of playing favourites in Greenbelt plans
Why we need parasites
The hunt for dark matter, two kilometres under Sudbury
The evolutionary advantage of curly hair
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME